Trial Profile
ADVATE 2 mL (Reconstituted in 2 mL SWFI) POST-AUTHORIZATION SAFETY SURVEILLANCE STUDY
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Octocog alfa (Primary)
- Indications Haemophilia A
- Focus Adverse reactions
- Acronyms PASS
- Sponsors Baxter Healthcare Corporation
- 09 Feb 2016 Status changed from recruiting to completed as per ClinicalTrials.gov record.
- 27 Mar 2014 New trial record